Witkin JM - Search Results

1

Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin.

Witkin JM, Leucke S, Thompson LK, Lynch RA, Ding C, Heinz B, Catlow JT, Gleason SD, Li X. Witkin JM, et al. CNS Neurol Disord Drug Targets. 2013 Jun;12(4):498-505. doi: 10.2174/1871527311312040008. CNS Neurol Disord Drug Targets. 2013. PMID: 23574162

2

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG. Tzavara ET, et al. Among authors: witkin jm. Br J Pharmacol. 2003 Feb;138(4):544-53. doi: 10.1038/sj.bjp.0705100. Br J Pharmacol. 2003. PMID: 12598408 Free PMC article.

3

Enhancement of antidepressant potency by a potentiator of AMPA receptors.

Li X, Witkin JM, Need AB, Skolnick P. Li X, et al. Among authors: witkin jm. Cell Mol Neurobiol. 2003 Jun;23(3):419-30. doi: 10.1023/a:1023648923447. Cell Mol Neurobiol. 2003. PMID: 12825836

4

A rapid punishment procedure for detection of anxiolytic compounds in mice.

Witkin JM, Morrow D, Li X. Witkin JM, et al. Psychopharmacology (Berl). 2004 Feb;172(1):52-7. doi: 10.1007/s00213-003-1618-4. Epub 2003 Sep 18. Psychopharmacology (Berl). 2004. PMID: 14504684

5

Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.

Gleason SD, Witkin JM. Gleason SD, et al. Among authors: witkin jm. Behav Pharmacol. 2004 Feb;15(1):85-9. doi: 10.1097/00008877-200402000-00010. Behav Pharmacol. 2004. PMID: 15075630

6

Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying.

Li X, Morrow D, Witkin JM. Li X, et al. Among authors: witkin jm. Life Sci. 2006 Mar 20;78(17):1933-9. doi: 10.1016/j.lfs.2005.08.002. Epub 2005 Sep 22. Life Sci. 2006. PMID: 16182315

7

A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.

Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. Witkin JM, et al. Trends Pharmacol Sci. 2005 Dec;26(12):609-17. doi: 10.1016/j.tips.2005.10.006. Epub 2005 Nov 2. Trends Pharmacol Sci. 2005. PMID: 16260047

8

In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. Alt A, et al. Among authors: witkin jm. Psychopharmacology (Berl). 2006 Apr;185(2):240-7. doi: 10.1007/s00213-005-0292-0. Epub 2006 Feb 10. Psychopharmacology (Berl). 2006. PMID: 16470401

9

Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine.

Gleason SD, Witkin JM. Gleason SD, et al. Among authors: witkin jm. Psychopharmacology (Berl). 2006 May;186(1):25-31. doi: 10.1007/s00213-006-0342-2. Epub 2006 Mar 31. Psychopharmacology (Berl). 2006. PMID: 16575553

10

Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice.

Li X, Need AB, Baez M, Witkin JM. Li X, et al. Among authors: witkin jm. J Pharmacol Exp Ther. 2006 Oct;319(1):254-9. doi: 10.1124/jpet.106.103143. Epub 2006 Jun 27. J Pharmacol Exp Ther. 2006. PMID: 16803860

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters